 |
市場調查報告書
商品編碼
1665178
緩釋輔料市場機會、成長動力、產業趨勢分析及 2024 - 2032 年預測Sustained-Release Excipients Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032 |
||||||
2024 年全球緩釋輔料市場規模達到 14 億美元，預計 2025 年至 2034 年的複合年成長率為 8.3%。緩釋輔料因其能夠在較長時間內控制藥物釋放的能力，在製藥業中變得越來越重要。隨著對有效的長期治療方案的需求不斷成長，這些賦形劑在旨在治療慢性病的藥物開發中變得不可或缺，最終增強治療效果。
隨著醫療保健提供者專注於提高患者依從性、減少副作用和最佳化治療方案，對緩釋藥物製劑的需求正在迅速增加。這些賦形劑提供了一個方便的解決方案，確保患者全天都能獲得所需的治療效果，而無需頻繁服藥。隨著全球慢性病的增加，緩釋製劑的採用預計會增加，使得緩釋輔料市場成為製藥業的關鍵部分。此外，藥物輸送系統和藥物成分的不斷進步有望提高緩釋輔料的整體有效性和功能性。
| 市場範圍 | |
|---|---|
| 起始年份 | 2023 |
| 預測年份 | 2024-2032 |
| 起始值 | 14億美元 |
| 預測值 | 30億美元 |
| 複合年成長率 | 8.3% |
市場分為幾個產品類別，包括聚合物、明膠、礦物質、糖和其他賦形劑。 2024年，聚合物引領市場，創造最高收入。聚合物因其多功能性而受到特別重視，因為它們可以根據特定患者的需求創建藥物釋放曲線。聚合物具有基質和塗層等多種結構可能性，被製藥公司廣泛用於開發創新的藥物輸送系統。這些系統不僅提高了藥物的有效性，而且有助於提高患者的依從性，這對於長期治療的成功至關重要。
就給藥途徑而言，緩釋輔料市場分為口服、靜脈（IV）、經皮、肌肉注射（IM）和其他形式。 2024 年口服給藥佔據市場主導地位，並貢獻了可觀的收入。由於給藥方便，且不需要專門的設備或培訓，口服藥物成為患者的首選。片劑和膠囊等口服劑型由於其舒適性和熟悉性而更加受歡迎。此外，口服途徑提供了更大的藥物吸收表面積，從而增強了緩釋製劑的整體有效性。
預計到 2034 年，美國緩釋輔料市場規模將達到 9.674 億美元。約有60%的成年人患有至少一種慢性疾病，對緩釋製劑的需求很大，以確保穩定的治療效果，同時減少服藥頻率。此外，藥物成分和藥物傳輸技術的不斷進步，提高了緩釋輔料的有效性，進一步推動了市場的成長。
目錄
第 1 章：方法論與範圍
第 2 章：執行摘要
第 3 章：產業洞察
- 產業生態系統分析
- 產業衝擊力
- 成長動力
- 慢性病盛行率不斷上升
- 控釋製劑需求不斷成長
- 技術進步
- 認知和接受度不斷提高
- 產業陷阱與挑戰
- 開發成本高
- 成長動力
- 成長潛力分析
- 監管格局
- 技術格局
- 創新格局
- 差距分析
- 波特的分析
- PESTEL 分析
第4章：競爭格局
- 介紹
- 公司市佔率分析
- 主要市場參與者的競爭分析
- 競爭定位矩陣
- 競爭儀錶板
第 5 章：市場估計與預測：按產品類型，2021 年至 2034 年
- 主要趨勢
- 聚合物
- 明膠
- 礦物質
- 糖
- 其他產品類型
第 6 章：市場估計與預測：按管理路線，2021 年至 2034 年
- 主要趨勢
- 口服
- 靜脈注射 (IV)
- 經皮
- 肌肉注射 (IM)
- 其他給藥途徑
第 7 章：市場估計與預測：按技術，2021 年至 2034 年
- 主要趨勢
- 定向投放
- 微囊化
- 植入物
- Wurster 技術
- 凝聚
- 其他技術
第 8 章：市場估計與預測：按應用，2021 年至 2034 年
- 主要趨勢
- 藥品
- 營養保健品
第 9 章：市場估計與預測：按地區，2021 年至 2034 年
- 主要趨勢
- 北美洲
- 美國
- 加拿大
- 歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
第10章：公司簡介
- BASF
- Ashland Global
- Colorcon
- Croda International
- DFE Pharma
- Eastman
- Evonik Industries
- FMC Corporation
- Gattefosse
- International Flavors & Fragrances
- JRS Pharma
- Merck
- Roquette
- Seppic
- Shin-Etsu Chemical
The Global Sustained-Release Excipients Market reached USD 1.4 billion in 2024 and is projected to exhibit a CAGR of 8.3% from 2025 to 2034. This market growth is primarily driven by the increasing prevalence of chronic diseases, such as diabetes, hypertension, and cardiovascular conditions, which demand long-term, ongoing medication management. Sustained-release excipients are becoming increasingly critical in the pharmaceutical industry due to their ability to provide controlled drug release over extended periods. As the need for effective, long-term treatment options continues to rise, these excipients are becoming indispensable in the development of drugs aimed at managing chronic conditions, ultimately enhancing therapeutic outcomes.
The demand for sustained-release drug formulations is rapidly increasing as healthcare providers focus on improving patient compliance, reducing side effects, and optimizing treatment regimens. These excipients offer a convenient solution, ensuring that patients receive the desired therapeutic effects throughout the day, without the need for frequent dosing. With chronic diseases on the rise globally, the adoption of sustained-release formulations is expected to increase, making the sustained-release excipients market a key segment in the pharmaceutical industry. Moreover, ongoing advancements in drug delivery systems and pharmaceutical ingredients are expected to enhance the overall effectiveness and functionality of sustained-release excipients.
| Market Scope | |
|---|---|
| Start Year | 2023 |
| Forecast Year | 2024-2032 |
| Start Value | $1.4 Billion |
| Forecast Value | $3 Billion |
| CAGR | 8.3% |
The market is divided into several product categories, including polymers, gelatin, minerals, sugars, and other excipients. In 2024, polymers led the market, generating the highest revenue. Polymers are especially valued for their versatility, as they allow for the creation of drug release profiles tailored to specific patient needs. With various structural possibilities, such as matrices and coatings, polymers are widely used by pharmaceutical companies to develop innovative drug delivery systems. These systems not only improve drug effectiveness but also contribute to better patient adherence, which is essential for long-term therapeutic success.
In terms of route of administration, the sustained-release excipients market is segmented into oral, intravenous (IV), transdermal, intramuscular (IM), and other forms. Oral administration dominated the market in 2024, with significant revenue contributions. The ease of administration, coupled with the lack of need for specialized equipment or training, makes oral medications a preferred choice for patients. The popularity of oral dosage forms such as tablets and capsules is further boosted by their comfort and familiarity. Additionally, the oral route provides a larger surface area for drug absorption, which enhances the overall effectiveness of sustained-release formulations.
The U.S. sustained-release excipients market is expected to reach USD 967.4 million by 2034. The country led the North American market in 2024, driven by a high prevalence of chronic diseases. With around 60% of adults affected by at least one chronic condition, the demand for sustained-release formulations is significant, ensuring stable therapeutic effects while reducing the frequency of dosing. Moreover, continuous advancements in pharmaceutical ingredients and drug delivery technologies are enhancing the effectiveness of sustained-release excipients, further fueling the market's growth.
Table of Contents
Chapter 1 Methodology and Scope
- 1.1 Market scope and definitions
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources
Chapter 2 Executive Summary
- 2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Increasing prevalence of chronic diseases
- 3.2.1.2 Rising demand for controlled-release formulations
- 3.2.1.3 Technological advancements
- 3.2.1.4 Growing awareness and acceptance
- 3.2.2 Industry pitfalls & challenges
- 3.2.2.1 High development cost
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.5 Technological landscape
- 3.6 Innovation landscape
- 3.7 Gap analysis
- 3.8 Porter’s analysis
- 3.9 PESTEL analysis
Chapter 4 Competitive Landscape, 2024
- 4.1 Introduction
- 4.2 Company market share analysis
- 4.3 Competitive analysis of major market players
- 4.4 Competitive positioning matrix
- 4.5 Competitive dashboard
Chapter 5 Market Estimates and Forecast, By Product Type, 2021 – 2034 ($ Mn)
- 5.1 Key trends
- 5.2 Polymers
- 5.3 Gelatin
- 5.4 Minerals
- 5.5 Sugars
- 5.6 Other product types
Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 – 2034 ($ Mn)
- 6.1 Key trends
- 6.2 Oral
- 6.3 Intravenous (IV)
- 6.4 Transdermal
- 6.5 Intramuscular (IM)
- 6.6 Other routes of administration
Chapter 7 Market Estimates and Forecast, By Technology, 2021 – 2034 ($ Mn)
- 7.1 Key trends
- 7.2 Targeted delivery
- 7.3 Microencapsulation
- 7.4 Implants
- 7.5 Wurster technique
- 7.6 Coacervation
- 7.7 Other technologies
Chapter 8 Market Estimates and Forecast, By Application, 2021 – 2034 ($ Mn)
- 8.1 Key trends
- 8.2 Pharmaceuticals
- 8.3 Nutraceuticals
Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)
- 9.1 Key trends
- 9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
- 9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
Chapter 10 Company Profiles
- 10.1 BASF
- 10.2 Ashland Global
- 10.3 Colorcon
- 10.4 Croda International
- 10.5 DFE Pharma
- 10.6 Eastman
- 10.7 Evonik Industries
- 10.8 FMC Corporation
- 10.9 Gattefosse
- 10.10 International Flavors & Fragrances
- 10.11 JRS Pharma
- 10.12 Merck
- 10.13 Roquette
- 10.14 Seppic
- 10.15 Shin-Etsu Chemical
